Letter to the Editor: No immunophenotyping in peripheral blood of prostate cancer patients treated with neoadjuvant Rituximab?

J Transl Med. 2020 Sep 1;18(1):333. doi: 10.1186/s12967-020-02496-5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Immunophenotyping
  • Male
  • Neoadjuvant Therapy*
  • Prostatic Neoplasms* / drug therapy
  • Rituximab / therapeutic use

Substances

  • Rituximab